Fortress Biotech, Inc. FBIOP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-12.29
Altman Z″ — distress risk · distress
9.7%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $63.3M | $6.8M | — | — | $62.2M |
| 2024 | $55.1M | -$46.0M | — | -$80.2M | -$1.6M |
| 2023 | $84.5M | -$60.6M | — | -$128.3M | $1.6M |
| 2022 | $75.7M | -$86.6M | — | -$182.1M | $50.0M |
| 2021 | $68.8M | -$64.7M | — | -$121.1M | $225.9M |
| 2020 | $45.6M | -$46.5M | — | -$85.6M | $197.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Jin David | Chief Financial Officer | 2026-06-22 | Grant | 400,000 | — |
| Jin David | Chief Financial Officer | 2026-04-01 | Grant | 2,967 | $2.18 |
| ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | 2026-03-18 | Grant | 475,424 | — |
| WEISS MICHAEL S | Executive Vice Chairman | 2026-03-18 | Grant | 475,424 | — |
| Fortress Biotech, Inc. | 10% owner | 2026-01-02 | Grant | 278,385 | — |
| Fortress Biotech, Inc. | 10% owner | 2026-01-02 | Grant | 111,209 | — |
| Hoenlein Malcolm | director | 2026-01-01 | Grant | 27,322 | — |
| Klein Dov | director | 2026-01-01 | Grant | 27,322 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.29 (distress)
- Working capital / assets 0.399
- Retained earnings / assets -3.956
- EBIT / assets -0.378
- Equity / liabilities 0.504
Source: SEC EDGAR filings · CIK 0001429260 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.